What Are Dave Lashmet’s Three Stocks to Make Triple-Digit Gains on Flash-Radioimmunotherapy?

Dave Lashmet from Stansberry Research has a major prediction: on October 23 will be released the results of a very first human trial that could make cancer treatment possible. He discovered three companies with exclusive patents in this field that could be worth $150 billion. Their stocks will skyrocket no matter what’s happening in the rest of the market.

Continue reading this article if you want to learn more about Dave’s prediction and how to use his knowledge to make money from healthcare market.

In a recent interview, Scott Garliss meets Dave Lashmet who has one of the most consistent track records at Stansberry Research. They talk about major cancer treatment discovery that you won’t hear anywhere else.

In fact, there are only two ways to learn about this huge potential breakthrough and money-making opportunity before it becomes widely popular:

One is by spending years studying medicine, establish connections, and conducting research.

The other one is by watching their presentation.

---

— RECOMMENDED —

How I Made $100,000 Overnight

It began with a mysterious phone call from a billionaire hedge-fund manager… desperate for access to Joel Litman’s stock market rating system before the next opening bell. What happened next would unlock a stock market phenomenon that spits out 10-, 20-, and even 30-baggers a few rare times per year. And right now, it’s happening again.

Just make sure you see this incredible story before tomorrow’s opening bell.

---

Dave Lashmet’s Most Valuable Science Discovery

Back in 2019 Dave witnessed a proof of concept for this research when it was presented to thousand of doctors for the first time.

By now he knows it works. Of course, there is no way to be certain. This is his speculation based on his research for almost a year. The clinical trial is over, the results of the first-in-human study of Proton Flash Radiotherapy are in.

Instead of publishing their findings in a peer-reviewed journal, the parties will present their data live in front of thousands of doctors and researchers on October 23rd.

These announcements could act as the catalyst to move markets. Money could flood into the companies behind this breakthrough, sending their stocks up as high as 400%.

Part One: The first huge announcement is about cancer immunotherapy. It is waking up your immune system to find heal from the cancer.

It uses a method called FLASH radiotherapy. In the first human trial, the tumor treated completely dissolved without any severe reaction much faster than the “normal” treatment time. And it is far less painful.

Part Two: The Second discovery came out of an annual conference in Orlando, FL back in 2015. At that time Dave met Dr. James Allison.

Dr. Allison is the harmonica-playing doctor from East Texas, who spent decades studying the immune system and how it works.

Today he is a PhD and Nobel Laureate. He discovered that the immune system could be rewired to recognize and fight cancer cells.

The one molecule responsible for triggering the immune system’s lethal reaction was discovered by him. He later created a medication to activate that kill response.

25% of patients in Dr. Allison’s phase one clinical trial experienced complete tumor remission…

You can consider that a breakthrough.

While Dr. Allison was working on his study, another molecule that also affects the immune system was found.

That molecule was named Programmed Death, PD for short.

Today, there are now 62 different immunotherapy drug approvals to treat cancer.

Just weeks ago, the results of one of these drugs made headlines after being published by the New England Journal of Medicine.

Not only did every single patient in the 12-person study respond to treatment, but every single patient had their tumors vanish.

How much are Dave’s discoveries worth for investors?

After Dave saw this first data, he added immunotherapy to his model portfolio before a single dollar of product was sold.

Since then, it’s generated over $130 billion in revenue and this year it is expected to peak past $30 billion in sales.

Everything comes down to TWO breakthrough treatments with three leading companies behind this technique.

It makes their patents some of the most valuable in history.

---

— RECOMMENDED —

Major Announcement From Dr. Steve Sjuggerud

“This is what I’m doing with my own money right now. I recommend you do the same”.

In a brand-new update, Dr. Steve Sjuggerud explains his No. 1 recommended sector that could reliably make you hundreds-of-percent gains in the coming months, no matter what the market does next.

See Steve’s urgent new message right here

---

The three companies that own 95% of the market share of the medicine

First one has won lawsuits against every top cancer drug maker that tried to copy their immunotherapy drug. Now, they collect a royalty on every single immunotherapy drug sold.

Furthermore, any business that succeeds in getting an immunotherapy medicine approved in the future will probably have to pay this business a royalty. This is the power of a patent and market dominance.

The other two companies own almost the entire flash-radiotherapy market. Their maintenance contracts will never run out.

It’s a very specialized industry to be there because every software update and firmware patch must receive FDA approval. This implies unlimited revenue streams.

Both companies gradually take over control of the radiotherapy market, which is expected to be worth $8.1 billion by 2027.

Every detail of these companies is covered in a brand-new report called Three Ways to Make Triple-Digit Gains on Flash-Radioimmunotherapy.

Source: stansberryresearch.com

What is Dave Lashmet’s secret weapon?

Dave can see both – the whole picture and the small details because he understands the technical aspects, the details other financial analysts can’t figure out.

He was a university professor. He studied HIV, AIDS, human genomics, history of medicine, patent law, infection disease, etc.

Dave has been listed as an inventor on three U.S. patents, including a new class of video game he sold to a consumer electronics giant.

He is a different tech investor. And his version of tech stocks is different, too.

He avoids Redfins and focuses on companies that are built on more than intellectual property. That’s why one of three picks Dave made ended at least a double. Few tech investors have these kinds of returns.

---

— RECOMMENDED —

Severe Stock Warning: A New Financial Crisis Is Underway

It doesn’t matter if you have money in the markets right now, or you’re waiting on the sidelines. The short period we’re about to enter could have the power to make – or destroy – fortunes. And what you do in the coming days could determine your wealth for the next decade. Here’s what’s happening and how to prepare.

Click here for details

---

Dave Lashmets’ Recommendations

Dave recommends the following steps you need to take immediately:

Step #1: Buy these three perfectly timed stocks.

To help you get started, Dave prepared a brand-new research report called Three Ways to Make Triple-Digit Gains on Flash-Radioimmunotherapy. Inside you will learn:

• The name and ticker of the ONE immunotherapy company getting paid on almost every single immunotherapy drug developed and sold in the markets.
• The names and tickers of the other TWO companies who have discovered and developed the first flash-radiotherapy devices. This market is so new, it’s sitting on $0 in sales. Right NOW, is the BEST time to invest.
• The exact details about what you need to do to position yourself before the rest of the world will learn what we believe to have discovered early.

Step #2: Position yourself for more gains.

Some of the biggest finds Dave uncovered are in health care sector. He has no doubt that the biggest gains ahead are going to be in this space.

Source: stansberryresearch.com

Look at this chart – over the last two decades, United Health Group (the biggest health care company in the world) posted consistent gains over 4,000 times bigger than those of the S&P 500.

Healthcare thrives on patents. Healthcare companies have the best tech, they constantly win existing markets and create new ones.

Major part of Dave’s job is meeting with scientists, sitting shoulder to shoulder with executives from top health agencies, attending conferences. He shares his discoveries in a one-of-a-kind research service called Stansburry Venture Technology.

When you join this service, Dave Lashmet will immediately send you your copy of his brand-new special report, Three Ways to Make Triple-Digit Gains of Flash-Radioimmunotherapy.

What is Stansberry Venture Technology?

The purpose of Stansberry Venture Technology research service is to give its subscribers access to “Venture Capital”- like opportunities in the markets.

Every month, they share their knowledge of small, unknown businesses that have a predictable cash stream but are poised to make the next major discovery.

Dave and his team find these companies before their names hit headlines.

If you are interested in investing in healthcare, Dave and his team are going to show you how to profit from every aspect of the future of health.

How much is Stansburry Venture Technology?

If you are serious about learning Dave’s way of picking reliable, consistent stocks, and are willing to get started now, visit this page where you will find a great deal – 55% OFF the retail price for a full year of access. If you get in before this offer expires, you can receive one full year of Stansberry Venture Technology for an extraordinary and rare 55% discount of just $2,500.

 

Source: stansberryresearch.com

What Is Included in The Special Offer of Stansburry Venture Technology?

 Here’s everything you’ll receive today:

55% OFF one year of Stansberry Venture Technology ($5,500 value)

You’ll get 12 monthly issues of Stansberry Venture Technology delivered to your inbox on the fourth Tuesday of every month, complete with research, updates, and analysis. Plus, Dave will send you any critical updates throughout the month if there is a breaking development with any of the tracked positions.

FREE one year access to the Stansberry Venture Technology model portfolio

You’ll also get instant access to Dave’s hand-picked model portfolio of the BEST stocks he’s selected to return at least 100% or more… even in today’s volatile market environment.

Three Ways to Make Triple-Digit Gains on Flash-Radioimmunotherapy

Dave has found the three companies to benefit from the announcement he expects on October 23.

And, with just three picks, you’ll own 95% of the brand-new flash-radioimmunotherapy market that could soon become the most effective treatment for cancer ever. His report contains the most detailed explanation into how you could take advantage of this almost perfect setup… when the very first flash radioimmunotherapy breakthrough study is revealed to the world. And it’s only days away, which means you have to move fast.

The Incredible Weight Loss Drug

Obesity is the greatest disease our generation will fight, as 42% of Americans have fallen victim in the last 30 years. But the very first approved drug will change everything… and finally win the war against one of the fastest-growing diseases in the world. Dave will share the stock and ticker of the ONE company that created the drug most Americans need right now.

The Fast-Tracked Cancer Antibody Drug with 250% Gain Potential

As an added bonus, Dave is including another incredible report from his extensive cancer research. Inside, he’ll reveal which company has developed the one antibody drug he believes has the potential to cure many different forms of cancer. This pick comes with 250% gain potential, an incredible bonus.

Stansberry Venture Technology Member Handbook

Dave’s approach to investing is one-of-a-kind… just like his results. No other investor that we know has been able to replicate Dave’s impeccable track record. To date, one in three stock picks Dave makes at least doubles… some have soared as high as 1,466%. In the Stansberry Venture Technology handbook, he reveals his strategy in alarming detail of just how he’s managed to see consistent results, in bear markets and bulls.

Special Updates, Reports, Issues, and Videos

As an added bonus, you’ll also immediately unlock Dave’s entire library of special reports and monthly issues. You’ll also get special BUY and SELL updates as news unfolds regarding Dave’s picks. Since the start of the year, Dave has already issued over 13 urgent updates… including a sell order to lock-in a 1,466% gain. This is why Dave’s work is revered as some of the most valuable Stansberry Research offers.

---

— RECOMMENDED —

Huge Recession Loophole (See These Charts)

Amid today’s market turmoil, THIS is one of the biggest and most bullish opportunities today: a red-hot sector with almost unlimited pricing power and a history of outperforming in recessions. It’s also the sector where our good friend Dr. David Eifrig spent half his professional life – meaning he’s extremely qualified to spot world-class opportunities today.

Take a look at the evidence here.

---

Is There Any Guarantee Or Refund Policy in Place?

You’re fully protected over the next 30 days to try this work…

Take the next 30 days and review everything Dave and Stansberry Research send you, including all of Dave’s new special reports, his trade recommendations, and his entire model portfolio.

There’s no cash refund!

If for any reason you’re not satisfied with Dave’s work, simply call Stansberry’s Customer service team and you’ll receive 100% of the money you spend right now back to you in the form of Stansberry Credit.

This credit can be applied toward any of the other Stansberry Research products of your choice over the next year.

Bottom line: Should You Join?

If you are interested in an industry that has for decades defied the odds in down markets, Dave and his Venture Technology service can point out solid companies with incredible breakthroughs.

To save your year, and yourself from the years of hardship ahead, you have to act now. If you are 50 or older, this research could pay for itself a hundred times.